Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses

Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot of people worldwide, resulting in COVID-19 vaccines being developed as an effort to stop the pandemic. The vaccines approved by the Mala...

Full description

Saved in:

Bibliographic Details
Main Author:	Izani, Wani Husna Mohd
Format:	Thesis
Language:	English
Published:	2023
Subjects:	R Medicine RC109-216 Infectious and parasitic diseases
Online Access:	http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.60291
record_format	uketd_dc
spelling	my-usm-ep.602912024-04-18T04:31:10Z Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses 2023-08 Izani, Wani Husna Mohd R Medicine RA440-440.87 Study and teaching. Research RC109-216 Infectious and parasitic diseases Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot of people worldwide, resulting in COVID-19 vaccines being developed as an effort to stop the pandemic. The vaccines approved by the Malaysian government include Sinovac CoronaVac and Pfizer-BioNTech BNT162b2. Vaccination can increase the level of neutralising antibodies and protect against COVID-19 infections. Neutralising antibodies are essential in monitoring the effectiveness of the vaccines against SARSCoV- 2. Several assays have been developed to detect neutralising antibody titres in individuals. The purpose of this study was to evaluate the two commercialized assays, GenScript cPass and ImmuSAFE COVID+ tests in detecting SARS-CoV-2 neutralising antibody titres. Both assays used a total of 26 serum samples of CoronaVac second (n = 13) and BNT162b2 booster (n = 13) doses. The study also determined neutralising antibody titres between males and females among young adults in second and booster doses. The results showed the titre of neutralising antibodies was higher in BNT162b2 booster dose than in CoronaVac second dose serum samples. The analysis of the demographic data showed neutralising antibody titres in females were higher than in males among young adults in second and booster dose samples. The study concluded that both assays were reliable in detecting neutralising antibodies in serum samples following vaccination. 2023-08 Thesis http://eprints.usm.my/60291/ http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	R Medicine R Medicine RC109-216 Infectious and parasitic diseases
spellingShingle	R Medicine R Medicine RC109-216 Infectious and parasitic diseases Izani, Wani Husna Mohd Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
description	Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot of people worldwide, resulting in COVID-19 vaccines being developed as an effort to stop the pandemic. The vaccines approved by the Malaysian government include Sinovac CoronaVac and Pfizer-BioNTech BNT162b2. Vaccination can increase the level of neutralising antibodies and protect against COVID-19 infections. Neutralising antibodies are essential in monitoring the effectiveness of the vaccines against SARSCoV- 2. Several assays have been developed to detect neutralising antibody titres in individuals. The purpose of this study was to evaluate the two commercialized assays, GenScript cPass and ImmuSAFE COVID+ tests in detecting SARS-CoV-2 neutralising antibody titres. Both assays used a total of 26 serum samples of CoronaVac second (n = 13) and BNT162b2 booster (n = 13) doses. The study also determined neutralising antibody titres between males and females among young adults in second and booster doses. The results showed the titre of neutralising antibodies was higher in BNT162b2 booster dose than in CoronaVac second dose serum samples. The analysis of the demographic data showed neutralising antibody titres in females were higher than in males among young adults in second and booster dose samples. The study concluded that both assays were reliable in detecting neutralising antibodies in serum samples following vaccination.
format	Thesis
qualification_level	Master's degree
author	Izani, Wani Husna Mohd
author_facet	Izani, Wani Husna Mohd
author_sort	Izani, Wani Husna Mohd
title	Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
title_short	Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
title_full	Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
title_fullStr	Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
title_full_unstemmed	Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
title_sort	evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and bnt162b2 booster doses
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2023
url	http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf
_version_	1804888906968072192

Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses

Similar Items